HOUSTON–(BUSINESS WIRE)–As older adults continue to age, it can be difficult for both them and their loved ones to distinguish between the signs and symptoms associated with ‘normal’ aging, such as stress and cognitive decline, and a common precursor to dementia called Mild Cognitive Impairment (MCI) – especially when it’s in its very early stages. … [Read more…]
CINCINNATI–(BUSINESS WIRE)–Chemed Corporation (“Chemed”) (NYSE:CHE) announced that it has entered into $550 million of amended and restated senior secured credit facilities (“Credit Facilities”). JPMorgan Chase Bank, N.A. acted as the Administrative Agent, and Lead-left Bookrunner and Joint Lead Arranger. Bank of America, N.A. acted as Co-Syndication Agent and Joint Bookrunner/Lead Arranger. PNC Bank National Association … [Read more…]
Inaugural grant awarded to the HealthTree Foundation, a pioneering non-profit organization whose proposal will address disparities in care in multiple myeloma PHILADELPHIA–(BUSINESS WIRE)–#Diversity–GSK plc today announced the first recipient of the Target the Future Think Tank Challenge £70,000 (equivalent to approximately $100,000) grant to the HealthTree Foundation, a non-profit organization helping patients learn more about … [Read more…]
FOOTHILL RANCH, Calif.–(BUSINESS WIRE)–TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today presented in vivo and in vitro boron delivery data using the company’s novel compounds at the 60th Particle Therapy Co-Operative Group (PTCOG) Conference, occurring June 27 – July 2, 2022. “The identification of these targeted … [Read more…]
SEATTLE–(BUSINESS WIRE)–Receptor Life Sciences (RLS), a clinical-stage pharmaceutical company developing innovative therapies to address central nervous system disorders, announced that the first patient has been dosed in its Phase 1b/2a clinical safety, tolerability, and efficacy study evaluating RLS103 in adult patients with acute anxiety within social anxiety disorder (SAD). RLS103, a dry powder inhaled cannabidiol … [Read more…]
GUAYNABO, Puerto Rico–(BUSINESS WIRE)–IACTA Pharmaceuticals, Inc. (“IACTA”), an innovation leader in ophthalmic therapeutics, today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of Dr. Richard L. Abbott and Dr. Lixin Xie. Dr. Abbott and Professor Xie join an established group of global advisors who will provide strategic insight and guidance to … [Read more…]
— STX-721 is a next-generation, highly selective Exon 20 mutant EGFR inhibitor designed for a best-in-class profile to overcome efficacy and toxicity limitations of currently available agents — — Approximately 3,400 patients per year diagnosed with NSCLC tumors that express EGFR with Exon 20 insertion mutations in the United States — — Preclinical data to … [Read more…]
Phase III COMFORT™ study met its primary endpoint with statistically significant improvement and Piclidenoson had an excellent safety profile Can-Fite has licensing deals for the marketing of Piclidenoson for the treatment of Psoriasis in multiple global regions PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of … [Read more…]
World’s only brain-guided heat shock protein induction could help millions affected with neurologic disorders AVENTURA, Fla.–(BUSINESS WIRE)–btt Corp. (btt), a medical technology company focused on the development of innovative devices and treatments for targeted heat shock protein induction, today announced that Oklahoma Rock Holdings, LLC (Oklahoma Rock) has completed an investment of $29.3 million. btt’s … [Read more…]
CAMBRIDGE, Mass. & NASHVILLE, Tenn.–(BUSINESS WIRE)–Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbinger’s novel platform technology for blood-based early cancer detection. The Cancer ORigin Epigenetics- Harbinger Health (CORE-HH) study plans … [Read more…]
